An Examination of Ventricular Assist Device Duration Prior to Heart Transplant in Children
Pediatric Cardiology · 2026-02 · 47 (2) · 612-623
DOI: 10.1007/s00246-025-03809-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Cardiology, online erschienen am 20.02.2025. Verfasst von Arene Butto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Children'S Healthcare of Atlanta, Atlanta, GA, USA. arene.butto@emory.edu. Hauptthemen laut MEDLINE: Heart Transplantation, Heart-Assist Devices, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Enduring Hearts Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Recent data demonstrate worse heart transplant (HTx) outcomes in children with shorter VAD durations, but do not account for VAD adverse events (AEs)Es. We compared outcomes of patients bridged to HTx with < 30 vs. ≥ 30 days of VAD support in an earlier era by assessing both VAD and HTx risk factors. We merged data from the PediMACS and Pediatric Heart Transplant Study registries to compare one-year post-HTx mortality in patients with < 30 vs. ≥ 30 days of pre-HTx VAD support between 2012 and 2018. We used inverse probability of treatment weighting using propensity scores (PS) to control for confounders, including age, blood type, allosensitization, cardiac diagnosis (cardiomyopathy, congenital heart disease, or myocarditis), VAD support type (left, right, single, or biventricular VAD), and pre-Tx mechanical ventilation and vasoactive support. Among 271 patients, there were 60 in the < 30-days and 211 in the ≥ 30-days groups. At HTx, the < 30-days group used more ventilation (34% vs. 7%, p < 0.001) and vasoactives (60% vs. 24%, p < 0.001 vs. ≥ 30-days). The weighted AE rate/patient was 0.42 in the < 30-days vs. 0.78 in the ≥ 30-days group (p = 0.02). There were 2 deaths in the < 30-days group and 13 in the ≥ 30-days group (p = 0.38). A PS-weighted Cox model, adjusted for 30-day VAD AE rate, demonstrated a non-significant mortality hazard ratio of 0.43 for < 30-days vs. ≥ 30-days group (95%CI 0.07-2.70, p = 0.37). In this era, there was no difference in survival based on VAD duration prior to HTx. This finding requires additional comparisons to the current era of VAD as a bridge to Tx.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Children'S Healthcare of Atlanta, Atlanta, GA, USA. arene.butto@emory.edu.
- Nationwide Children'S Hospital, Columbus, OH, USA.
- Children'S Healthcare of Atlanta, Atlanta, GA, USA.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
- Medical University of South Carolina, Charleston, SC, USA.
- University of California San Diego, Redlands, CA, USA.
Förderung
- Enduring Hearts Foundation
Zitieren
APA
Butto, A., Wright, L. K., Mao, C. Y., Keesari, R., Adams, V., Chau, P., Desai, M., Dipchand, A. I., Edelson, J. B., Rose-Felker, K., Simpson, K. E., & Mahle, W. T. (2026). An Examination of Ventricular Assist Device Duration Prior to Heart Transplant in Children. Pediatric Cardiology, 47(2), 612-623. https://doi.org/10.1007/s00246-025-03809-5
Vancouver
Butto A, Wright LK, Mao CY, Keesari R, Adams V, Chau P, et al. An Examination of Ventricular Assist Device Duration Prior to Heart Transplant in Children. Pediatric Cardiology. 2026;47(2):612-623. doi:10.1007/s00246-025-03809-5
BibTeX
@article{Butto2026,
author = {Butto, Arene and Wright, Lydia K and Mao, Chad Y and Keesari, Rohali and Adams, Vanessa and Chau, Peter and Desai, Manan and Dipchand, Anne I and Edelson, Jonathan B and Rose-Felker, Kirsten and Simpson, Kathleen E and Mahle, William T},
title = {An Examination of Ventricular Assist Device Duration Prior to Heart Transplant in Children},
journal = {Pediatric Cardiology},
year = {2026},
volume = {47},
number = {2},
pages = {612--623},
doi = {10.1007/s00246-025-03809-5}
}
EUVIMED